StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Monday morning. The brokerage issued a hold rating on the stock.

A number of other research firms have also weighed in on DBVT. JMP Securities upped their target price on DBV Technologies from $4.00 to $5.00 and gave the stock a market outperform rating in a report on Wednesday, July 31st. HC Wainwright reissued a buy rating and issued a $5.00 price target on shares of DBV Technologies in a research report on Thursday, August 1st.

DBV Technologies Price Performance

DBVT stock opened at $0.87 on Monday. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $3.70. The business has a 50-day moving average price of $0.89 and a 200 day moving average price of $1.21. The company has a market capitalization of $83.95 million, a P/E ratio of -1.04 and a beta of 0.68.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. During the same quarter in the prior year, the firm posted ($0.26) EPS. On average, analysts anticipate that DBV Technologies will post -1.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. raised its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.